Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer R Hamilton

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Science (New York, N.Y.)|February 8, 2020
Knocking out barriers to engineered cell activityJennifer R Hamilton, Jennifer A Doudna
Cell Reports|January 4, 2018
A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse ModelJennifer R Hamilton, Gayathri Vijayakumar, Peter Palese
Journal of Virology|October 11, 2013
NFX1-123 and human papillomavirus 16E6 increase Notch expression in keratinocytesPortia A Vliet-Gregg, Jennifer R Hamilton, Rachel A Katzenellenbogen
Virology|February 28, 2015
Human papillomavirus 16E6 and NFX1-123 potentiate Notch signaling and differentiation without activating cellular arrestPortia A Vliet-Gregg, Jennifer R Hamilton, Rachel A Katzenellenbogen
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2024
Targeted nonviral delivery of genome editors in vivoConnor A Tsuchida, Kevin M Wasko, Jennifer R Hamilton, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2016
Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunityJennifer R Hamilton, David Sachs, Jean K Lim, et al.
Nature Microbiology|July 31, 2019
DNA mismatch repair is required for the host innate response and controls cellular fate after influenza virus infectionBenjamin S Chambers, Brook E Heaton, Keiko Rausch, et al.
Nature Biotechnology|January 11, 2024
In vivo human T cell engineering with enveloped delivery vehiclesJennifer R Hamilton, Evelyn Chen, Barbara S Perez, et al.
Molecular Therapy. Methods & Clinical Development|January 15, 2020
Targeting Antigen to the Surface of EVs Improves the <i>In Vivo</i> Immunogenicity of Human and Non-human Adenoviral Vaccines in MiceCarly M Bliss, Andrea J Parsons, Raffael Nachbagauer, et al.
Cell Reports|June 2, 2021
Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineeringJennifer R Hamilton, Connor A Tsuchida, David N Nguyen, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Science (New York, N.Y.)|February 8, 2020
Knocking out barriers to engineered cell activityJennifer R Hamilton, Jennifer A Doudna
Cell Reports|January 4, 2018
A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse ModelJennifer R Hamilton, Gayathri Vijayakumar, Peter Palese
Journal of Virology|October 11, 2013
NFX1-123 and human papillomavirus 16E6 increase Notch expression in keratinocytesPortia A Vliet-Gregg, Jennifer R Hamilton, Rachel A Katzenellenbogen
Virology|February 28, 2015
Human papillomavirus 16E6 and NFX1-123 potentiate Notch signaling and differentiation without activating cellular arrestPortia A Vliet-Gregg, Jennifer R Hamilton, Rachel A Katzenellenbogen
Proceedings of the National Academy of Sciences of the United States of America|March 4, 2024
Targeted nonviral delivery of genome editors in vivoConnor A Tsuchida, Kevin M Wasko, Jennifer R Hamilton, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2016
Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunityJennifer R Hamilton, David Sachs, Jean K Lim, et al.
Nature Microbiology|July 31, 2019
DNA mismatch repair is required for the host innate response and controls cellular fate after influenza virus infectionBenjamin S Chambers, Brook E Heaton, Keiko Rausch, et al.
Nature Biotechnology|January 11, 2024
In vivo human T cell engineering with enveloped delivery vehiclesJennifer R Hamilton, Evelyn Chen, Barbara S Perez, et al.
Molecular Therapy. Methods & Clinical Development|January 15, 2020
Targeting Antigen to the Surface of EVs Improves the <i>In Vivo</i> Immunogenicity of Human and Non-human Adenoviral Vaccines in MiceCarly M Bliss, Andrea J Parsons, Raffael Nachbagauer, et al.
Cell Reports|June 2, 2021
Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineeringJennifer R Hamilton, Connor A Tsuchida, David N Nguyen, et al.
Pageof 3